Company intelligence / Profile preview
AUTOTAC Bio
Seoul, South Koreaautotacbio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Currently in preclinical and early clinical development. AB 19 is in preclinical trials for Progressive supranuclear palsy in South Korea, with plans for Phase I trials between 2024-2025 and Phase II trials between 2025-2026. ATC-324 has shown promising results in degrading androgen receptors in prostate cancer models.
- Therapeutic areas
- OncologyImmunologyRare DiseasesNeurology
- Modalities
- Small moleculesprotein degraderschimeric molecules
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on AUTOTAC Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AUTOTAC Bio.